ID   PNMT_HUMAN              Reviewed;         282 AA.
AC   P11086;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Phenylethanolamine N-methyltransferase;
DE            Short=PNMTase;
DE            EC=2.1.1.28;
DE   AltName: Full=Noradrenaline N-methyltransferase;
GN   Name=PNMT; Synonyms=PENT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3372503;
RA   Kaneda N., Ichinose H., Kobayashi K., Oka K., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Molecular cloning of cDNA and chromosomal assignment of the gene for
RT   human phenylethanolamine N-methyltransferase, the enzyme for
RT   epinephrine biosynthesis.";
RL   J. Biol. Chem. 263:7672-7677(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RA   Sasaoka T., Kaneda N., Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Structure of human phenylethanolamine N-methyltransferase gene:
RT   existence of two types of mRNA with different transcription initiation
RT   sites.";
RL   Neurochem. Int. 15:555-565(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2835776; DOI=10.1073/pnas.85.10.3648;
RA   Baetge E.E., Behringer R.R., Messing A., Brinster R.L., Palmiter R.D.;
RT   "Transgenic mice express the human phenylethanolamine N-
RT   methyltransferase gene in adrenal medulla and retina.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3648-3652(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE AND SYNTHETIC INHIBITOR.
RX   PubMed=11591352; DOI=10.1016/S0969-2126(01)00662-1;
RA   Martin J.L., Begun J., McLeish M.J., Caine J.M., Grunewald G.L.;
RT   "Getting the adrenaline going: crystal structure of the adrenaline-
RT   synthesizing enzyme PNMT.";
RL   Structure 9:977-985(2001).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE
RP   ANALOGS AND S-ADENOSYL-L-HOMOCYSTEINE, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND MUTAGENESIS OF TYR-35; GLU-185; GLU-219 AND ASP-267.
RX   PubMed=16363801; DOI=10.1021/bi051636b;
RA   Gee C.L., Tyndall J.D.A., Grunewald G.L., Wu Q., McLeish M.J.,
RA   Martin J.L.;
RT   "Mode of binding of methyl acceptor substrates to the adrenaline-
RT   synthesizing enzyme phenylethanolamine N-methyltransferase:
RT   implications for catalysis.";
RL   Biochemistry 44:16875-16885(2005).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=16942016; DOI=10.1021/jm060466d;
RA   Grunewald G.L., Seim M.R., Regier R.C., Martin J.L., Gee C.L.,
RA   Drinkwater N., Criscione K.R.;
RT   "Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-
RT   tetrahydroisoquinolines with their isosteric sulfonamides to the
RT   active site of phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 49:5424-5433(2006).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEXES WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=17845018; DOI=10.1021/jm0703385;
RA   Gee C.L., Drinkwater N., Tyndall J.D.A., Grunewald G.L., Wu Q.,
RA   McLeish M.J., Martin J.L.;
RT   "Enzyme adaptation to inhibitor binding: a cryptic binding site in
RT   phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 50:4845-4853(2007).
RN   [10]
RP   VARIANTS SER-9; ALA-98; CYS-112 AND THR-175, AND CHARACTERIZATION OF
RP   VARIANT ALA-98.
RX   PubMed=16277617; DOI=10.1111/j.1471-4159.2005.03453.x;
RA   Ji Y., Salavaggione O.E., Wang L., Adjei A.A., Eckloff B.,
RA   Wieben E.D., Weinshilboum R.M.;
RT   "Human phenylethanolamine N-methyltransferase pharmacogenomics: gene
RT   re-sequencing and functional genomics.";
RL   J. Neurochem. 95:1766-1776(2005).
CC   -!- FUNCTION: Converts noradrenaline to adrenaline.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + phenylethanolamine =
CC       S-adenosyl-L-homocysteine + N-methylphenylethanolamine.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=99 uM for phenylethanolamine {ECO:0000269|PubMed:16363801};
CC         KM=3.4 uM for S-adenosyl-L-methionine
CC         {ECO:0000269|PubMed:16363801};
CC   -!- PATHWAY: Catecholamine biosynthesis; (R)-adrenaline biosynthesis;
CC       (R)-adrenaline from (R)-noradrenaline: step 1/1.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. NNMT/PNMT/TEMT family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03727; AAA60130.1; -; mRNA.
DR   EMBL; X52730; CAA36944.1; -; Genomic_DNA.
DR   EMBL; J03280; AAA60131.1; -; Genomic_DNA.
DR   EMBL; BC037246; AAH37246.1; -; mRNA.
DR   CCDS; CCDS11343.1; -.
DR   PIR; A28171; A28171.
DR   RefSeq; NP_002677.1; NM_002686.4.
DR   UniGene; Hs.1892; -.
DR   PDB; 1HNN; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 1N7I; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 1N7J; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 1YZ3; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2AN3; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN4; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN5; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 2G70; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2G71; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2G72; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 2G8N; X-ray; 2.15 A; A/B=1-282.
DR   PDB; 2OBF; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 2ONY; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 2ONZ; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 2OPB; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 3HCA; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCB; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCC; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3HCD; X-ray; 2.39 A; A/B=1-282.
DR   PDB; 3HCE; X-ray; 2.85 A; A/B=1-282.
DR   PDB; 3HCF; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 3KPJ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KPU; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPV; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPW; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPY; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQM; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQO; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQP; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQQ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KQS; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 3KQT; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQV; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KQW; X-ray; 2.49 A; A/B=1-282.
DR   PDB; 3KQY; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 3KR0; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 3KR1; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KR2; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 4DM3; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 4MIK; X-ray; 1.95 A; A/B=1-282.
DR   PDB; 4MQ4; X-ray; 2.20 A; A/B=1-282.
DR   PDBsum; 1HNN; -.
DR   PDBsum; 1N7I; -.
DR   PDBsum; 1N7J; -.
DR   PDBsum; 1YZ3; -.
DR   PDBsum; 2AN3; -.
DR   PDBsum; 2AN4; -.
DR   PDBsum; 2AN5; -.
DR   PDBsum; 2G70; -.
DR   PDBsum; 2G71; -.
DR   PDBsum; 2G72; -.
DR   PDBsum; 2G8N; -.
DR   PDBsum; 2OBF; -.
DR   PDBsum; 2ONY; -.
DR   PDBsum; 2ONZ; -.
DR   PDBsum; 2OPB; -.
DR   PDBsum; 3HCA; -.
DR   PDBsum; 3HCB; -.
DR   PDBsum; 3HCC; -.
DR   PDBsum; 3HCD; -.
DR   PDBsum; 3HCE; -.
DR   PDBsum; 3HCF; -.
DR   PDBsum; 3KPJ; -.
DR   PDBsum; 3KPU; -.
DR   PDBsum; 3KPV; -.
DR   PDBsum; 3KPW; -.
DR   PDBsum; 3KPY; -.
DR   PDBsum; 3KQM; -.
DR   PDBsum; 3KQO; -.
DR   PDBsum; 3KQP; -.
DR   PDBsum; 3KQQ; -.
DR   PDBsum; 3KQS; -.
DR   PDBsum; 3KQT; -.
DR   PDBsum; 3KQV; -.
DR   PDBsum; 3KQW; -.
DR   PDBsum; 3KQY; -.
DR   PDBsum; 3KR0; -.
DR   PDBsum; 3KR1; -.
DR   PDBsum; 3KR2; -.
DR   PDBsum; 4DM3; -.
DR   PDBsum; 4MIK; -.
DR   PDBsum; 4MQ4; -.
DR   ProteinModelPortal; P11086; -.
DR   SMR; P11086; -.
DR   BioGrid; 111410; 3.
DR   IntAct; P11086; 4.
DR   STRING; 9606.ENSP00000269582; -.
DR   BindingDB; P11086; -.
DR   ChEMBL; CHEMBL4617; -.
DR   DrugBank; DB08129; (1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol.
DR   DrugBank; DB01752; S-Adenosyl-L-Homocysteine.
DR   GuidetoPHARMACOLOGY; 2496; -.
DR   iPTMnet; P11086; -.
DR   PhosphoSitePlus; P11086; -.
DR   DMDM; 130375; -.
DR   PaxDb; P11086; -.
DR   PeptideAtlas; P11086; -.
DR   PRIDE; P11086; -.
DR   DNASU; 5409; -.
DR   Ensembl; ENST00000269582; ENSP00000269582; ENSG00000141744.
DR   GeneID; 5409; -.
DR   KEGG; hsa:5409; -.
DR   UCSC; uc002hsi.3; human.
DR   CTD; 5409; -.
DR   DisGeNET; 5409; -.
DR   GeneCards; PNMT; -.
DR   HGNC; HGNC:9160; PNMT.
DR   HPA; CAB017029; -.
DR   HPA; HPA043412; -.
DR   HPA; HPA051005; -.
DR   MIM; 171190; gene.
DR   neXtProt; NX_P11086; -.
DR   OpenTargets; ENSG00000141744; -.
DR   PharmGKB; PA274; -.
DR   eggNOG; ENOG410IJGY; Eukaryota.
DR   eggNOG; ENOG4111F9R; LUCA.
DR   GeneTree; ENSGT00390000011708; -.
DR   HOGENOM; HOG000013229; -.
DR   HOVERGEN; HBG000797; -.
DR   InParanoid; P11086; -.
DR   KO; K00553; -.
DR   OMA; FAWAQKK; -.
DR   OrthoDB; EOG091G0EF7; -.
DR   PhylomeDB; P11086; -.
DR   TreeFam; TF313114; -.
DR   BioCyc; MetaCyc:HS06868-MONOMER; -.
DR   BRENDA; 2.1.1.28; 2681.
DR   Reactome; R-HSA-209905; Catecholamine biosynthesis.
DR   UniPathway; UPA00749; UER00736.
DR   EvolutionaryTrace; P11086; -.
DR   GenomeRNAi; 5409; -.
DR   PRO; PR:P11086; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141744; -.
DR   CleanEx; HS_PNMT; -.
DR   ExpressionAtlas; P11086; baseline and differential.
DR   Genevisible; P11086; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004603; F:phenylethanolamine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0042423; P:catecholamine biosynthetic process; TAS:Reactome.
DR   GO; GO:0042418; P:epinephrine biosynthetic process; IEA:UniProtKB-UniPathway.
DR   InterPro; IPR025820; NNMT/PNMT/TEMT_CS.
DR   InterPro; IPR000940; NNMT_TEMT_trans.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PANTHER; PTHR10867; PTHR10867; 1.
DR   Pfam; PF01234; NNMT_PNMT_TEMT; 1.
DR   PIRSF; PIRSF000384; PNMTase; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS01100; NNMT_PNMT_TEMT; 1.
DR   PROSITE; PS51681; SAM_MT_NNMT_PNMT_TEMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Catecholamine biosynthesis; Complete proteome;
KW   Methyltransferase; Phosphoprotein; Polymorphism; Reference proteome;
KW   S-adenosyl-L-methionine; Transferase.
FT   CHAIN         1    282       Phenylethanolamine N-methyltransferase.
FT                                /FTId=PRO_0000159709.
FT   REGION       79     80       S-adenosyl-L-methionine binding.
FT   REGION      158    159       S-adenosyl-L-methionine binding.
FT   BINDING      35     35       S-adenosyl-L-methionine.
FT   BINDING      40     40       S-adenosyl-L-methionine.
FT   BINDING      85     85       S-adenosyl-L-methionine.
FT   BINDING     101    101       S-adenosyl-L-methionine.
FT   BINDING     106    106       S-adenosyl-L-methionine.
FT   BINDING     181    181       S-adenosyl-L-methionine; via carbonyl
FT                                oxygen.
FT   BINDING     219    219       Substrate.
FT   MOD_RES       7      7       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT       9      9       N -> S (in dbSNP:rs11569781).
FT                                {ECO:0000269|PubMed:16277617}.
FT                                /FTId=VAR_029351.
FT   VARIANT      98     98       T -> A (lower activity levels than wild-
FT                                type; dbSNP:rs36060376).
FT                                {ECO:0000269|PubMed:16277617}.
FT                                /FTId=VAR_036829.
FT   VARIANT     112    112       R -> C (in dbSNP:rs34530498).
FT                                {ECO:0000269|PubMed:16277617}.
FT                                /FTId=VAR_036830.
FT   VARIANT     175    175       A -> T (in dbSNP:rs34341496).
FT                                {ECO:0000269|PubMed:16277617}.
FT                                /FTId=VAR_036831.
FT   VARIANT     188    188       S -> C (in dbSNP:rs5639).
FT                                /FTId=VAR_037611.
FT   VARIANT     211    211       L -> H (in dbSNP:rs5640).
FT                                /FTId=VAR_037612.
FT   VARIANT     217    217       L -> Q (in dbSNP:rs5641).
FT                                /FTId=VAR_037613.
FT   VARIANT     254    254       R -> H (in dbSNP:rs5642).
FT                                /FTId=VAR_037614.
FT   VARIANT     276    276       W -> R (in dbSNP:rs5643).
FT                                /FTId=VAR_024547.
FT   MUTAGEN      35     35       Y->F: Strongly increases KM for substrate
FT                                and S-adenosyl-L-methionine.
FT                                {ECO:0000269|PubMed:16363801}.
FT   MUTAGEN     185    185       E->A,Q: Strongly reduced enzyme activity.
FT                                Increases affinity for S-adenosyl-L-
FT                                methionine.
FT                                {ECO:0000269|PubMed:16363801}.
FT   MUTAGEN     185    185       E->D: Strongly reduced enzyme activity.
FT                                Decreases affinity for substrate and S-
FT                                adenosyl-L-methionine 3-fold.
FT                                {ECO:0000269|PubMed:16363801}.
FT   MUTAGEN     219    219       E->A: Reduced enzyme activity. Decreases
FT                                affinity for substrate 6-fold. Decreases
FT                                affinity for S-adenosyl-L-methionine 2-
FT                                fold. {ECO:0000269|PubMed:16363801}.
FT   MUTAGEN     267    267       D->A,N: Strongly reduced enzyme activity.
FT                                Decreases affinity for substrate 200-
FT                                fold. Decreases affinity for S-adenosyl-
FT                                L-methionine 3-fold.
FT                                {ECO:0000269|PubMed:16363801}.
FT   CONFLICT    169    170       SP -> AQ (in Ref. 3; AAA60131).
FT                                {ECO:0000305}.
FT   HELIX        17     25       {ECO:0000244|PDB:4MIK}.
FT   HELIX        27     29       {ECO:0000244|PDB:4MIK}.
FT   HELIX        32     40       {ECO:0000244|PDB:4MIK}.
FT   TURN         42     45       {ECO:0000244|PDB:4MIK}.
FT   HELIX        53     66       {ECO:0000244|PDB:4MIK}.
FT   STRAND       73     79       {ECO:0000244|PDB:4MIK}.
FT   HELIX        85     87       {ECO:0000244|PDB:4MIK}.
FT   HELIX        90     92       {ECO:0000244|PDB:4MIK}.
FT   STRAND       95    100       {ECO:0000244|PDB:4MIK}.
FT   HELIX       104    114       {ECO:0000244|PDB:4MIK}.
FT   HELIX       124    134       {ECO:0000244|PDB:4MIK}.
FT   HELIX       140    150       {ECO:0000244|PDB:4MIK}.
FT   STRAND      151    155       {ECO:0000244|PDB:4MIK}.
FT   STRAND      161    163       {ECO:0000244|PDB:4MIK}.
FT   STRAND      173    182       {ECO:0000244|PDB:4MIK}.
FT   TURN        184    186       {ECO:0000244|PDB:4MIK}.
FT   HELIX       191    202       {ECO:0000244|PDB:4MIK}.
FT   STRAND      205    218       {ECO:0000244|PDB:4MIK}.
FT   STRAND      221    224       {ECO:0000244|PDB:4MIK}.
FT   STRAND      227    230       {ECO:0000244|PDB:4MIK}.
FT   HELIX       236    246       {ECO:0000244|PDB:4MIK}.
FT   STRAND      248    257       {ECO:0000244|PDB:4MIK}.
FT   HELIX       260    262       {ECO:0000244|PDB:4MIK}.
FT   STRAND      265    267       {ECO:0000244|PDB:4MIK}.
FT   STRAND      271    279       {ECO:0000244|PDB:4MIK}.
SQ   SEQUENCE   282 AA;  30855 MW;  56F3A9981D9ABF4C CRC64;
     MSGADRSPNA GAAPDSAPGQ AAVASAYQRF EPRAYLRNNY APPRGDLCNP NGVGPWKLRC
     LAQTFATGEV SGRTLIDIGS GPTVYQLLSA CSHFEDITMT DFLEVNRQEL GRWLQEEPGA
     FNWSMYSQHA CLIEGKGECW QDKERQLRAR VKRVLPIDVH QPQPLGAGSP APLPADALVS
     AFCLEAVSPD LASFQRALDH ITTLLRPGGH LLLIGALEES WYLAGEARLT VVPVSEEEVR
     EALVRSGYKV RDLRTYIMPA HLQTGVDDVK GVFFAWAQKV GL
//
